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Botulinum neurotoxins (BoNT) serotypes C and D and their mosaic variants CD and DC 32 
cause severe cases of botulism in animal husbandry and wildlife. Epidemiological data on 33 
the exact serotype or toxin variant causing outbreaks are rarely available, mainly because of 34 
their high sequence identity and the lack of fast and specific screening tools to detect and 35 
differentiate the four similar toxins. To fill this gap, we developed four highly specific 36 
sandwich enzyme-linked immunosorbent assays (ELISAs) able to detect and differentiate 37 
botulinum neurotoxins type BoNT/C, D, CD, and DC based on four distinct combinations of 38 
specific monoclonal antibodies targeting both conserved and divergent subdomains of the 39 
four toxins. Here, highly sensitive detection with detection limits between 2 and 24 pg/mL 40 
was achieved. The ELISAs were extensively validated and results were compared with data 41 
obtained by quantitative real-time PCR using a panel of Clostridium botulinum strains, real 42 
sample materials from veterinary botulism outbreaks, and non-BoNT-producing Clostridia. 43 
Additionally, in order to verify the results obtained by ELISA screening, the new monoclonal 44 
antibodies were used for BoNT enrichment and subsequent detection (i) on a functional level 45 
by endopeptidase mass spectrometry (Endopep-MS) assays and (ii) on a protein sequence 46 
level by LC-MS/MS spectrometry. Based on all technical information gathered in the 47 
validation study, the four differentiating ELISAs turned out to be highly reliable screening 48 
tools for the rapid analysis of veterinary botulism cases and should aid future field 49 





Botulism, a potentially life-threatening paralytic disease in men and animals, is caused by the 53 
complex family of high molecular weight botulinum neurotoxins (BoNTs) which cleave and 54 
thereby functionally inactivate essential molecules within the neurotransmitter release 55 
machinery. All BoNTs are synthesised as single molecules of 150 kDa. Upon activation by a 56 
protease they form di-chain toxins composed of a 50 kDa light chain (LC) with zinc-57 
dependent protease activity, linked via a disulphide bond to the 100 kDa heavy chain (HC), 58 
comprising an N-terminal translocation domain (HN) and a C-terminal receptor binding 59 
domain (HC).1 The BoNTs can be distinguished into seven confirmed serotypes, A through G. 60 
While BoNT/A, B, E, and F predominantly cause botulism in humans, serotypes BoNT/C and 61 
D have been attributed to veterinary botulism.2, 3 Rare evidence points towards naturally 62 
occurring botulism in man to be associated with serotypes C or D, but the relevance of the 63 
historic data is questionable.4 Although natural intoxication with BoNT/C and D does not 64 
seem to occur in man, it has been shown that experimental intoxication with BoNT/C can 65 
cause botulism symptoms in humans.5, 6 On the other hand, serotypes C and D can cause 66 
mass outbreaks in farm animals and frequently in waterfowls.7-9 Animal botulism can even 67 
threaten already endangered species.10-12 Genetic analysis of the neurotoxin genes of 68 
BoNT/C and D revealed that, apart from BoNT/C and BoNT/D, two highly related mosaic 69 
variants called BoNT/CD and BoNT/DC exist13-15 in which the first letter designates the 70 
catalytic activity and the second letter the receptor-binding activity13. For BoNT/C and CD, 71 
two thirds of the molecules are highly identical (LC and HN domains, identity >92%), while the 72 
HC domains are less conserved (>40%, Figure 1). Similarly, BoNT/D and DC show a high 73 
identity in their LC and HN domains (>94%) and reduced conservation in the HC domains 74 
(>37%). Conversely, the HC domains of BoNT/D and CD are highly homologous (>91%, 75 
Figure 1), while the HC domains of BoNT/C and DC are less conserved (overall 74%), 76 
containing a region of lower homology (58%) at nucleotide positions 3485–3800 encoding 77 
the C-terminal portion of BoNT/C HC (HC/C).14 These mosaic structures explain many of the 78 
puzzling observations of cross-reactivity of antisera and antibodies in the past. With respect 79 
to epidemiologic investigation of veterinary botulism outbreaks, only very few studies have 80 
been published, demonstrating that BoNT/CD and DC seem to be predominant in Europe 81 
and Japan in avian and bovine botulism.16-24 82 
The BoNTs are produced by the Gram-positive, anaerobic, spore-forming organism 83 
Clostridium (C.) botulinum and strains of C. baratii and C. butyricum. For more than 100 84 
years morphological, physiological, and biochemical differences between C. botulinum 85 
strains have been recognised, and modern genomic analyses have revealed that 86 
C. botulinum can be separated into four Groups I to IV25: The proteolytic strains of Group I 87 
 
 
produce BoNT/A, B, and F, while the non-proteolytic Group II strains produce BoNT/B, E, 88 
and F. Group III strains are linked to serotypes C and D and their mosaics, while BoNT/G is 89 
produced by Group IV.26 On the basis of 16S rRNA homology, genomic and phenotypical 90 
relatedness all four groups have non-BoNT-producing counterparts lacking the neurotoxin 91 
gene cluster but are assigned to different species names.26 Depending on the particular 92 
strain, the neurotoxin gene cluster can be encoded in mobile genetic elements such as 93 
plasmids or phage, but can also be incorporated into the bacterial chromosome.27 Loss of the 94 
neurotoxin gene cluster which has been reported for Groups I, II, and III transforms 95 
C. botulinum to a different species. In particular for Group III where the BoNT gene cluster is 96 
located on a pseudo-lysogenic phage, loss of the BoNT gene cluster and thus loss of 97 
neurotoxicity has been described frequently.14, 28, 29 Additionally, interconversion between 98 
C. botulinum serotypes C and D and conversion of C. novyi (non-toxigenic) into C. botulinum 99 
(toxigenic) by infection with the corresponding phage are possible.30-32 Due to the similarities 100 
on genomic and phenotypic level, the organisms compiling C. botulinum Group III, C. novyi, 101 
and C. haemolyticum have been designated C. novyi sensu lato.29  102 
After reaching the neuromuscular junction, BoNT first accumulates via binding to complex 103 
polysialo-gangliosides on the surface of motoneurons and subsequently endocytose via 104 
interaction with protein receptors into small synaptic vesicles.33 For all serotypes except for 105 
BoNT/C, a proteinaceous cell surface receptor on the neuronal cell surface has been 106 
identified that is bound with high affinity. Noteworthy, while the HC/DC has been shown to 107 
bind synaptotagmin I and II, no such interaction was found for the HC/C despite their high 108 
homology.34 In contrast, the HC/C fragment recognises two gangliosides employing two 109 
distinct binding pockets.35-37 Also HC of BoNT/D and CD bind two gangliosides but with much 110 
lower affinity than HC/C.38, 39 One glycolipid interaction might be substituted by binding 111 
synaptic vesicle protein 2 (SV2).40 After internalisation, the HN domain of HC conveys the 112 
translocation of the LC into the cytosol. The LC harbours the catalytic endopeptidase activity 113 
towards the so-called soluble NSF attachment protein receptor (SNARE) molecules, thus 114 
preventing fusion of the neurotransmitter-loaded vesicles with the synaptic membrane. Unlike 115 
other BoNTs which cleave either the synaptic proteins synaptosomal-associated protein of 116 
25 kDa (SNAP-25) or synaptobrevin-2/vesicle-associated membrane protein-2 (VAMP-2) at 117 
distinct, individual positions, BoNT/C and BoNT/CD are the only known neurotoxins that 118 
target two different synaptic molecules: SNAP-25 and syntaxin.41 BoNT/C and BoNT/CD 119 
hydrolyse SNAP-25 between amino acid positions Arg198 and Ala199 and syntaxin between 120 
positions Lys253 and Ala254.41 In the case of BoNT/D and DC, the enzymatic cleavage site 121 
has been localised between positions Lys59 and Leu60 of VAMP-2.41 122 
 
 
C. botulinum strains are found ubiquitously in soil and marine sediments and are able to 123 
induce human and veterinary botulism cases worldwide. Whereas numerous assays have 124 
been established42 for the detection and discrimination of the BoNT serotypes pathogenic to 125 
humans (serotypes A, B, E, and F), targeting either the coding DNA or the BoNT proteins, 126 
the situation is different for the detection of serotypes BoNT/C and D. In particular, assays 127 
distinguishing between BoNT/C, D, and the mosaic variants CD and DC are sparse. Only 128 
very few conventional and quantitative PCR methods have been reported to be able to 129 
discriminate between these four toxin variants.19, 20, 43 Convenient detection and 130 
differentiation of BoNT/C, D, and their mosaic variants on protein level is an unresolved issue 131 
so far, but this would be highly important for a number of reasons: (i) DNA-based assays 132 
cannot distinguish between a low-level contamination with the bacterium and the growth and 133 
active toxin production; (ii) the level of toxin produced cannot be determined based on 134 
genetic data; (iii) certain C. botulinum cultures or individual suspected samples may have lost 135 
their phage carrying the BoNT gene locus, thus turning PCR negative while the culture 136 
supernatant might still be toxic; (iv) in some strains, silent genes have been described that 137 
encode a non-functional toxin.44 Therefore, genetic information is indicative of toxin-138 
producing Clostridia, but results can be ambiguous. The gold standard for toxin detection is 139 
still the mouse bioassay, which is time consuming, expensive, unable to deal with high 140 
sample numbers, and questionable under ethical considerations. Additionally, the clear 141 
differentiation of BoNT/C or D as well as discrimination of mosaic forms has been impaired 142 
due to cross-reactivity of antibodies used for neutralisation. To date, only a few 143 
immunoassays have been described which can detect some, but not all of the four BoNTs 144 
relevant in the context of veterinary botulism. Immunochromatographic assays and sandwich 145 
enzyme-linked immunosorbent assays (ELISAs) have been described, performed either 146 
plate-bound or on magnetic beads, detecting both BoNT/C and/or D.45-49 Recently, Nakamura 147 
et al. reported the development of rapid immunochromatographic tests for the detection and 148 
differentiation of BoNT/CD and DC18 and Zhang et al. a multiplex ELISA for six BoNT 149 
serotypes including BoNT/C and DC.50 A specific combination of appropriate sandwich 150 
ELISAs for detection and differentiation of all four BoNTs relevant in the context of veterinary 151 
botulism is lacking so far. 152 
As an alternative approach, assays addressing the functional activity of BoNT have been 153 
developed which detect the endopeptidase activity of the LC coupled to different read-outs. 154 
Very promising is the combination of immunoaffinity enrichment of BoNT by antibody-155 
coupled magnetic beads plus detection of the in vitro cleavage of artificial SNARE substrates 156 
by mass spectrometry (MS), the Endopep-MS assay.51 The assay is highly sensitive, and – 157 
by using cross-reactive antibodies for enrichment – can determine the type of LC activity 158 
(BoNT/C- or D-type activity). A different access for toxin detection lies in its identification by 159 
 
 
tryptic peptide fingerprint and its amino acid sequence using an MS/MS proteomics 160 
approach.51 However, the proteomics approach is often hampered by its lower analytic 161 
sensitivity compared to the Endopep-MS assay. In this context, Björnstad and co-workers 162 
very recently described the use of two parallel immunocapture reactions based on two 163 
monoclonal antibodies (mAbs) either recognising all four BoNT variants (BoNT/C, D, CD, and 164 
DC) or recognising BoNT/C and BoNT/DC only. In combination with the Endopep-MS assay, 165 
they were able to enrich and distinguish between the four veterinary BoNTs with good 166 
sensitivities.22 The sophisticated approach is a clear technological advancement; still it might 167 
be restricted to expert laboratories with access to expensive MS-based instrumentation and 168 
dedicated expertise.  169 
The aim of our study was to develop fast, easy, and precise ELISA-based screening tools for 170 
the detection and differentiation of BoNT/C, D, and their respective mosaic variants that can 171 
be applied in routine veterinary laboratories. To this end, highly specific monoclonal 172 
antibodies were developed which differentially bind to LC or HC of the four BoNT proteins. 173 
Proper combinations of the antibodies led to four individual ELISAs, one of them specifically 174 
detecting BoNT/C, the second detecting BoNT/CD, the third detecting BoNT/D, and the 175 
fourth detecting BoNT/DC only. The four ELISAs were thoroughly validated on a panel of 176 
C. botulinum strains and real veterinary samples with respect to sensitivity and specificity, 177 
and no cross-reactivity was observed. In a second approach, the set of monoclonal 178 
antibodies was used to corroborate the ELISA-based screening results by Endopep-MS 179 
assays which were able to functionally discriminate between BoNT/C, D, CD, and DC. In a 180 
validation study, the ELISA data were correlated with PCR data and Endopep-MS data on 181 




Toxins, bacterial supernatants, and primary culture enrichments 184 
BoNTs are highly toxic and therefore require appropriate safety measures. All toxins were 185 
handled by trained personnel under a class II vertical laminar flow cabinet (Heraeus 186 
Herasafe, Thermo Scientific, Dreieich, Germany) in a dedicated toxin laboratory. Toxin-187 
containing solutions were inactivated in 5% sodium hydroxide overnight, liquids containing 188 
Clostridia and/or spores as well as solid waste containing traces of toxin or Clostridia/spores 189 
were inactivated by autoclaving (134 °C, 1 h).  190 
Purified BoNT/A, B, C, DC, E, F, and G as well as the corresponding neurotoxin protein 191 
complexes were obtained from Metabiologics (Madison, WI, USA). The commercially 192 
available BoNT/DC is sold as “BoNT/D” but has been identified as BoNT/DC by mass 193 
spectrometry51. 194 
All recombinant BoNT/C proteins are based on the coding DNA sequence in the phage from 195 
C. botulinum strain 468, and BoNT/D proteins are based on the coding DNA sequence in the 196 
phage from strain BVD/-3 identical to that of strain 1873. Non-toxic HCCS (aa 867–1291 197 
fused to a C-terminal Strep-tag52), ‘HC/C’ in this manuscript, BoNTCS-Thro wildtype (active 198 
single chain [sc] BoNT/C fused to a Strep-tag and thrombin cleavage site53), ‘scBoNT/C’ in 199 
this manuscript, non-toxic HC/DS (aa 863–1276 fused to a C-terminal Strep-tag54), ‘HC/D’ in 200 
this manuscript and sc BoNT/D wild type with native loop sequence (scBoNTDSL38) were 201 
produced as described previously.38 In order to eliminate catalytic activity, three mutations 202 
each were introduced into scBoNTCS-Thro (= E230A/R372A/Y375F) and scBoNTDSL 203 
(= E230A/R372A/Y375F), yielding inactive scBoNT/Ci and scBoNT/Di. Absence of biological 204 
activity was examined employing the mouse phrenic nerve hemidiaphragm assay. 205 
Recombinant BoNT/CD (scH6tBoNTCDtS; strain 003-9), LC/C6xHN (aa 1–436), and 206 
LC/D6xHN (aa 1–436) were purchased from toxogen GmbH (Hannover, Germany). 207 
Bacterial cell culture supernatants were prepared from C. botulinum (Groups I, II, III, and IV), 208 
C. baratii, C. berijerinckii, C. botulinum Group II atoxic, C. butyricum, C. bifermentans, 209 
C. difficile, C. glycolicum, C. hiranonis, C. innocuum, C. novyi, C. paraputrificum, 210 
C. perfringens, C. sartagoforme, C. scindens, C. septicum, C. sordellii, C. sporogenes, 211 
C. subterminale, C. tertium, and C. tetani raised in tryptone-peptone-glucose-yeast extract 212 
(TPGY) medium for 1 to 7 days at 30 °C under anaerobic conditions in an anaerobic 213 
workstation (MACS 500, Don Whitley Scientific, Shipley, West Yorkshire, United Kingdom). 214 
Supernatants were collected by removing vegetative bacteria, using centrifugation (12,000 × 215 
g, 5 min, 4 °C) and two filtration steps (0.45 µm and 0.2 µm). A total of 23 primary culture 216 
enrichments from swabs, spleen, intestine, liver, and faeces from birds and cattle were 217 
collected from animal botulism outbreaks mainly from France and Germany over the last few 218 




Isolation and sequence analysis of strain 08084L-60 Eppendorf 221 
From a confirmed outbreak of botulism among cattle in Eppendorf, Germany, in 2008, tissue 222 
biopsy material was obtained from the Institut für Lebensmittel, Arzneimittel und 223 
Tierseuchen, Berlin. Cooked meat medium (Oxoid, Basingstoke, United Kingdom) was 224 
inoculated with organ sample material, and subsequently the C. botulinum group III strain 225 
08084L-60 Eppendorf was isolated. Organ material and the isolated strain were initially 226 
tested positive for BoNT/D or DC by TaqMan-PCR55, a test which is not distinctive between 227 
both forms. Genomic DNA was isolated as described before56 and subjected to whole 228 
genome sequencing on an Ion Torrent platform (Life Technologies, Darmstadt, Germany). 229 
Sequencing reads were imported into Geneious 7.1.4 (Biomatters, Auckland, New Zealand) 230 
and assembled on the neurotoxin gene cluster of strain CB-19 (Genbank AB745665).18 231 
Reads were re-assembled on the resulting neurotoxin gene cluster sequence. Comparison of 232 
the final sequence of the BoNT gene with Genbank entries revealed that it belongs to the DC 233 
mosaic type. The sequence of the BoNT/DC gene of strain 08084L-60 Eppendorf is available 234 
from Genbank under accession number KT355686.  235 
 236 
Sequence analysis 237 
For sequence comparison, the following Genbank entries were used for BoNT/C: AP008983 238 
(Stockholm), X71126 (A028), X53751 (468C); for BoNT/CD: AB745659 (OTZ07), FN436022 239 
(S19), AY251553 (TW/2003), CP002411 (BKT015925), D49440 (6813), AB745666 (003–9), 240 
AB745667 (348); for BoNT/DC: AB037920 (D-4947), AB745668 (OFD05), D38442 (South 241 
African), AB745669 (OFD16), LC008286 (OFD40), KT355686 (Eppendorf); and finally for 242 
BoNT/D: AB012112 (1873), S49407 (CB16). Sequences were uploaded into the Geneious 243 
7.1.4 software package, protein sequences were aligned and distances calculated using 244 
built-in Geneious Multiple Sequence Alignment algorithm (Global alignment with free end 245 
gaps; BLOSUM 6257). For amino acid sequence comparison of BoNT domains, whole 246 
alignment was tailored to contain the LC (aa 1–446), HC (aa 446–1293), HN (aa 446–867), or 247 
HC (aa 868–1293) based on sequence D49440.  248 
 249 
Quantitative real-time PCR 250 
DNA was purified from culture supernatants with the DNeasy Blood & Tissue Kit (Qiagen, 251 
Hilden, Germany) according to the manufacturer’s recommendation for Gram-positive 252 
bacteria. Alternatively, 200 µL of culture were centrifuged (12.000 × g, 5 min at 4 °C), the 253 
sediment washed with 200 µL of PBS and boiled for 15 min in 200 µL of H2O to release DNA. 254 
Quantitative real-time TaqMan PCR for bont/A–G was performed as described earlier.55 For 255 
 
 
the detection of bont/G, the following primers and probe were selected based on Genbank 256 
X7416258: forward primer: 5’-TGGCCATTCCCCAATATCA-3’,  257 
reverse primer: 5’-GGATCGCTATGTTGCATGAAAAA-3’,  258 
and probe: FAM-TAGACGCGCGTATTTTGCAGATCCAGC-BHQ1. In order to discriminate 259 
bont/C, CD, DC, and D at the genomic level, quantitative PCR was performed on a GeneDisc 260 
cycler (Qiagen) as described before. 20, 43 261 
 262 
Animal experiments 263 
Animal experiments were performed in compliance with the German Animal Welfare Act and 264 
European legislation for the protection of animals used for scientific purposes (Directive 265 
2010/63/EU). Experiments were evaluated and approved by the State Office for Health and 266 
Social Affairs in Berlin (LaGeSo Berlin, Germany) under registration numbers H109/03 267 
(production of antibodies) and A0073/08 (mouse bioassay). 268 
 269 
Generation of monoclonal antibodies  270 
Monoclonal antibodies (mAb) were generated according to standard procedures.59 Briefly, 271 
BALB/c or NMRI mice bred under pathogen-free conditions at Charles River (Sulzfeld, 272 
Germany) were used at the age of 8 weeks. Four female mice were immunised 273 
intraperitoneally (i.p.) with 25 µg or 50 µg of recombinant HC/C and/or 10 µg of scBoNT/Ci 274 
and 10 µg of scBoNT/Di in adjuvant as indicated in Table 1. Mice were boosted several times 275 
with similar doses of the same antigen i.p. in adjuvant at four-week intervals. On day –3, –2, 276 
and –1 before fusion, 25 µg or 50 µg of HC/C or 10 µg of scBoNT/Ci, and 10 µg of scBoNT/Di 277 
in phosphate-buffered saline (PBS) were applied i.p. daily. Hybridomas were produced by 278 
fusing spleen cells from immunised mice with myeloma cells (P3-X63-Ag8.653, American 279 
Type Culture Collection) at a ratio of 2:1 in polyethylene glycol 1500 (PEG, Roche 280 
Diagnostics, Mannheim, Germany) according to standard procedures.59 Antigen-specific mAb 281 
were screened by an indirect ELISA against the corresponding toxins at days 10 to 14 post-282 
fusion, and positive hybridoma clones were subcloned at least twice (Table 1). 283 
Immunoglobulins (IgG) were purified from hybridoma supernatants grown in RPMI media 284 
supplemented with IgG-free foetal bovine serum by affinity chromatography over a HiTrap 285 
MabSelect SuRe column using an Äkta Protein Purification System (GE Healthcare Bio-286 
Sciences AB, Uppsala, Sweden). L. Bellanger, CEA, kindly provided mAbs which were 287 
generated by immunising BALB/c mice (Charles River, Lyon, France) with recombinantly 288 
expressed HC/C and HC/D fragments purified from E. coli. The isotype of all purified 289 
monoclonal antibodies (mAbs) was determined using an IsoStrip mouse monoclonal 290 
antibody isotyping kit (Roche Applied Science, Mannheim, Germany). Antibodies were 291 
coupled to biotin according to the manufacturer’s instructions (EZ-Link Sulfo-NHS-LC-biotin; 292 
 
 
Pierce, Rockford, IL, USA). Biotinylated antibodies were stored in PBS with 0.2% (w/v) 293 
bovine serum albumin (BSA; Serva, Heidelberg, Germany) and 0.05% (w/v) NaN3 (Carl Roth, 294 
Karlsruhe, Germany). 295 
 296 
Surface plasmon resonance measurements (Biacore) 297 
Kinetics and affinity of antibody–antigen interaction were analysed by surface plasmon 298 
resonance (SPR) technology using a Biacore X100 unit (GE Healthcare, Freiburg, Germany) 299 
at 25 °C. For all experiments HBS-EP+ buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 300 
0.05% Tween-20, pH 7.4) was used as running buffer. mAbs were immobilised as ligands 301 
onto flow cell 2 (Fc2) of a biosensor chip using a mouse antibody capture kit (GE 302 
Healthcare), resulting in 100 to 300 resonance units (RU). Fc1 channel (anti-mouse capture 303 
antibody only) was set as blank control. Three-fold serial dilutions of analytes (scBoNT/C or 304 
scBoNT/Di) ranging from 200 to 0.82 nM were injected over both flow cells for 60 s at 305 
30 µL/min; time course of binding dissociation was monitored for 600 or 1200 s after running 306 
buffer injection. Microchip sensor surfaces were regenerated by injection of 10 mM glycine-307 
HCl buffer pH 1.7 (GE Healthcare) for 180 s with 10 µL/min over both flow cells prior to every 308 
new injection cycle. Reproducibility and retained activity of the sensor surface was controlled 309 
by duplicate measurement at the highest analyte concentration. Before data analysis, RUs of 310 
Fc2 were referenced to Fc1; in addition, three blank injections without antigen were used as 311 
a second reference. Kinetic binding parameters were determined by fitting the double 312 
referenced binding curves to the 1:1 Langmuir binding model (A + B = AB) by using the 313 
Biacore X100 evaluation software 1.1 (GE Healthcare, Uppsala, Sweden). To account for 314 
small differences in maximum binding capacity due to the usage of the mouse capture kit, 315 
Rmax was fitted locally. 316 
 317 
Indirect enzyme-linked immunosorbent assay (ELISA) 318 
MaxiSorp microtitre plates (F96; Nunc, Wiesbaden, Germany) were coated with antigen (500 319 
ng/mL, 50 µL per well) in PBS containing 1 µg/mL of BSA at 4 °C overnight and blocked with 320 
blocking buffer (PBS containing 0.1% Tween 20, 2% skimmed milk [Merck, Darmstadt, 321 
Germany]) for 1 h59. After washing with PBS containing 0.1% Tween 20 (PBST), the antibody 322 
was added (10 µg/mL in blocking buffer) for 1 h and was detected by horseradish peroxidase 323 
(HRP)-labelled goat anti-mouse IgG (Fc-γ specific; Dianova, Hamburg, Germany) and 324 
3,3’,5,5’-tetramethylbenzidine (TMB, SeramunBlau slow, Seramun, Heidesee, Germany). 325 
The average absorbance was measured at 450 nm and referenced to absorbance of 326 





Sandwich ELISA 330 
MaxiSorp microtitre plates were coated with primary mAb C394 (anti-LC/C), HCC10S or 331 
HCC2378 (both anti-HC/C), or D63 (anti-LC/D) at 5 µg/mL in 50 µL of PBS (pH 7.2) at 4 °C 332 
overnight. After blocking with casein buffer (Diavita, Heidelberg, Germany) at room 333 
temperature for 1 h and a following washing step with PBST, 50 µL of toxin was added in 334 
duplicate in serial dilutions from 1 mg/L to 1 ng/L or, for bacterial supernatants, diluted 1:10 335 
or 1:100 in assay buffer (PBS, 0.1% BSA). After 2 h at room temperature, cavities were 336 
washed and incubated at room temperature for 1 h with biotinylated secondary mAb C9 (anti-337 
HC/C), D63 (anti-LC/D), or D967 (anti-HC/D) diluted in casein buffer at 1 µg/mL, followed by 338 
washing and amplified detection with streptavidin-coupled horseradish peroxidase (SA-339 
PolyHRP40 [Senova, Weimar, Germany] or SA-POD [Dianova, Hamburg, Germany]) at 340 
0.2 µg/mL for 30 min. TMB was used as substrate and measurement was performed as 341 
above. 342 
 343 
Validation of sandwich ELISA  344 
For statistical analysis, we measured standard curves for each sandwich ELISA in ten 345 
independent runs over 10 days, with three replicates per concentration. Differences in 346 
absorbance at 450 and 620 nm were plotted against the log concentration of the BoNT 347 
standard and fitted against a sigmoidal dose–response curve (4-parametric non-linear 348 
regression analysis) in Prism 5.04 (GraphPad, La Jolla, CA, USA). The limit of detection 349 
(LOD) was calculated from the regression curve by adding 3.29-fold of the standard 350 
deviations to the mean of the absorbance (A450-620 nm) of ten determinations of blanks 351 
performed in duplicate on one microtitre plate. The lower and upper limits of quantification 352 
(LLOQ and ULOQ) flank the linear range of the sigmoidal curve between the inflection points 353 
of the 1st derivative of the sigmoidal regression curve and were computed as the maxima and 354 
minima of the 2nd derivative. The intra-assay coefficient of variation (CV% intra at EC50) was 355 
determined as the standard deviation divided by the mean of concentrations of ten double 356 
determinations of the half maximal effective concentrations (EC50) within plates, multiplied by 357 
100. The inter-assay coefficient of variation (CV% inter at EC50) was calculated 358 
correspondingly with concentrations measured between ten separate and independent runs. 359 
Statistically outlying concentration values were identified by Grubbs tests60 on a significance 360 
level of 0.05 using the R package ‘outliers’61 and excluded from the calculation of CVs. 361 
 362 
Immunoblot 363 
LC and HC domains of BoNT/C and BoNT/D were separated by 10% SDS-PAGE under non-364 
reducing conditions and transferred onto an Immuno-Blot 0.45 µm PVDF membrane 365 
(Invitrogen, Karlsruhe, Germany). After blocking the membrane in blocking buffer (2% 366 
 
 
skimmed milk in PBST) at 4 °C overnight, appropriately diluted primary antibody in blocking 367 
buffer was added to the membrane for 1 h. After three washing steps, the membrane was 368 
incubated with biotin-labelled goat anti-mouse IgG (Dianova, Hamburg, Germany) in blocking 369 
buffer at room temperature for 30 min and was developed with avidin-alkaline phosphatase 370 
and CDP-Star (Perkin Elmer, Waltham, MA, USA). 371 
 372 
Mouse bioassay  373 
Culture supernatants from primary enrichment cultures or isolated strains were diluted in 374 
PBS containing 0.1% BSA and injected i.p. into female BALB/c mice. Animals were closely 375 
monitored for typical botulism symptoms (wasp-like narrowed waist, laboured breathing, and 376 
beginning paralysis) for up to 4 days. When typical symptoms of botulism were observed 377 
animals were sacrificed according to human end-points. 378 
 379 
Toxin extraction with antibody-coated magnetic beads  380 
Different mAbs were immobilised to M-280 tosyl-activated paramagnetic Dynabeads 381 
(Invitrogen, Karlsruhe, Germany) following the manufacturer’s protocol as described earlier62: 382 
mAb C394 directed against the LC of BoNT/C and CD; mAb D63 (anti-LC of BoNT/D and 383 
DC); and mAb HCC2378 (anti-HC of BoNT/C and DC) or mAb D967 (anti-HC of BoNT/D and 384 
CD). To determine the catalytic activity (C-type or D-type) by Endopep-MS assay without 385 
differentiation of mosaics, 200 µL of bacterial culture supernatant or primary enrichment 386 
culture was added to 300 µL of PBST containing a mixture of both anti-LC antibody-coated 387 
beads (10 µL of mAb C394 plus 10 µL of mAb D63 beads). For differentiation of BoNT/C, 388 
CD, DC, and D, two independent antibody-based enrichment reactions were performed in 389 
parallel using the anti-HC antibody-coated beads (either mAb HCC2378 or mAb D967, 20 µL 390 
each). As negative control TPGY medium without toxin was used. After end-over-end 391 
incubation at room temperature for 1 h, the beads were washed twice in 1 mL of PBST, twice 392 
in PBS, and finally in 100 µL of distilled water. For naturally contaminated samples, beads 393 
were additionally washed twice in 1 mL of PBST with 2 M NaCl after PBST washing to 394 
remove unspecific bindings.63 The beads were reconstituted in 20 µL of Endopep reaction 395 
buffer.  396 
 397 
Endopep-MS analysis 398 
Endopep-MS analysis was performed according to Moura et al. and Hedeland et al.24, 51 with 399 
slight modifications. In brief, beads were reconstituted in 20 µL of reaction buffer containing 400 
20 mM HEPES (pH 7.4), 0.2 M ZnCl2, 10 mM dithiothreitol, 1 mg/mL BSA, and 50 pmol/µL of 401 
each BoNT/C and BoNT/D peptide substrate. Peptides (HPLC-purified, purity > 95%) were 402 
synthesised by peptides & elephants (Potsdam, Germany) or Dr Petra Henklein (Institute for 403 
 
 
Biochemistry, Charité Universitätsmedizin, Berlin, Germany). The reaction solution was 404 
started at 47 °C for 10 min, followed by incubation at 42 °C for 17 h using a thermocycler. 405 
The cleavage substrate for light chain activity of BoNT/C or BoNT/CD was modified from the 406 
human SNAP-25 protein sequence (Biotin-KGSNRTRIDEANQRATRMLGGK-biotin; m/z 407 
2911)51 and yielded the N-terminal (NT) cleavage product at m/z 1871 (Biotin-408 
KGSNRTRIDEANQR) and C-terminal (CT) one at m/z 1059 (ATRMLGGK-biotin). For light 409 
chain activity of BoNT/D and BoNT/DC, peptide substrate based on the sequence of the 410 
VAMP-2 protein (LQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL; m/z 4496)64 411 
was used; NT cleavage product is m/z 3297 (LQQTQAQVDEVVDIMRVNVDKVLERDQK); 412 
and CT cleavage product is m/z 1217 (LSELDDRADAL).  413 
 414 
Mass spectrometry detection 415 
MS-based Endopep analysis was done in MS-positive ion reflector mode utilizing an autoflex 416 
speed matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass 417 
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with a smartbeam laser. 418 
Sample (2 µL) was mixed with 18 µL of MALDI-Matrix (5 mg/mL of α-Cyano-4-419 
hydroxycinnamic acid, Bruker Daltonics) in 0.1% trifluoroacetic acid (TFA, Sigma-Aldrich, 420 
Seelze, Germany) and 50% acetonitrile (Carl Roth, Karlsruhe, Germany) in HPLC water, 421 
1 mM ammoniumphosphate (Merck, Darmstadt, Germany). Of this mixture 1 µL was spotted 422 
onto a MTP 384 polished steel target plate (Bruker Daltonics). For matrix suppression, 423 
deflection was set to m/z 500, mass spectra were acquired over the mass range m/z 600 to 424 
4800. External mass calibration was performed with peptide calibration standard II (Bruker 425 
Daltonics). Each spectrum represents an average of 4,000 laser shots. Spectra were 426 
processed by flexAnalysis 3.4 software (Bruker Daltonics). 427 
 428 
LC-MS/MS analysis of tryptic digest  429 
For liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, 500 µL of 430 
bacterial culture supernatant was mixed with 50 µL of 10× PBST, 20 µL of C394 beads or 431 
D63 beads and incubated under rotation at room temperature for 1 h. Beads were washed 432 
twice in 1 mL of HBS-EP buffer (GE Healthcare), once in 1 mL of distilled water and were 433 
reconstituted in 15 μL of 50 mM ammonium bicarbonate (pH 7.5). Tryptic digestion was 434 
performed at 52 °C for 5 min with 5 μL of 0.2 µg/µL trypsin (Sigma-Aldrich, Munich, 435 
Germany). After digestion, beads were removed and 2 μL of 10% TFA was added to the 436 
peptide solution. Prior to LC-MS/MS analysis 10 μL of peptide solution was loaded onto a 437 
trap column (Proxeon Thermo Scientific EASY-nLC C18, 5 μm nano LC column, 100 μm ID, 438 
and 2 cm long) and separated on an analytic column (Acclaim PepMap100 C18, 3 μm nLC 439 
column, 75 μm ID, and 15 cm long [Thermo Fisher Scientific, Dreieich, Germany]). Elution 440 
 
 
was achieved by formation of a binary gradient of buffer A (water with 0.1% formic acid) and 441 
buffer B (99.9% acetonitrile with 0.1% formic acid) with a flow rate of 300 nL/min: B = 2% at 0 442 
min; B = 40% at 60 min; B = 80% at 62 min; hold for 10 min; B = 2% at 74 min; hold for 5 443 
min. The nano LC was coupled online to an LTQ-Orbitrap Discovery mass spectrometer 444 
equipped with a nanoelectrospray ion source (both from Thermo Fisher Scientific, Bremen, 445 
Germany). For all measurements, the analyser was operated in data-dependent acquisition 446 
mode. After a survey scan in the Orbitrap (resolution of 30,000 from m/z 300 to 1,700) 447 
MS/MS fragmentation data was recorded for the seven most intensive precursor ions in the 448 
linear ion trap at collision-induced energy of 35%. Database search was performed using 449 
MASCOT Server 2.4 software (Matrix Science Ltd., London, United Kingdom). A database 450 
was compiled by extracting entries from the UniProt database using “clostridium botulinum” 451 
as search term and from the NCBI non-redundant database specific for BoNT/C, CD, D, and 452 
DC. Database search was performed with up to two missed tryptic cleavages, and 453 
methionine oxidation was set as variable modification. Peptides with up to +4 charge ions 454 
were used, precursor tolerance was set to 10 ppm and tolerance for fragment ions was set to 455 




Results and Discussion 458 
Generation and characterisation of monoclonal antibodies specific for fragments of 459 
BoNT/C and D  460 
In order to develop ELISA-based assays for detection and differentiation of all four BoNTs 461 
pathogenic for animals, we developed monoclonal antibodies (mAb) specifically binding to 462 
the LC or the HC-fragment of BoNT/C and BoNT/D, respectively. Technically challenging is 463 
the fact that, depending on the fragment analysed, BoNT/C, D, and their mosaic variants 464 
show a high degree of identity on the protein level65, as summarised in Figure 1 on the basis 465 
of different GenBank entries (three sequences for BoNT/C, seven sequences for BoNT/CD, 466 
two sequences for BoNT/D, and six sequences for BoNT/DC). BoNT/C and BoNT/CD are 467 
96.9–97.7% identical in their LC and 92.6–93.6% in their HN-domain, while the HC-domain of 468 
BoNT/C is only 40.0–40.4% identical to the HC-domain of BoNT/CD, which is 91.6–95.6% 469 
identical to HC/D. Similarly, BoNT/D and BoNT/DC are 97.8–98.2% identical in their LC and 470 
94.8–95.5% in their HN-domain, while the HC-domain of BoNT/D is 37.9–38.9% identical to 471 
the HC-domain of BoNT/DC, the latter being more closely related to the HC-domain of 472 
BoNT/C (73.8–74.0% identity). 473 
Classically, immunisation strategies to produce antibodies started by using formaldehyde-474 
inactivated purified toxins.45, 66, 67 While this allowed the application of sufficient amounts of 475 
antigen to trigger an immune response, the altered 3-dimensional structure often resulted in 476 
antibodies preferentially recognising the denatured toxoid over the native toxin. To overcome 477 
this drawback, non-toxic subdomains and here particularly the HC-fragments of BoNT/C or D 478 
have been used to generate monoclonal or polyclonal antibodies68 or to identify vaccine 479 
candidates.69-72 Only BoNT/C and BoNT/DC were commercially available as purified proteins 480 
from C. botulinum culture supernatants (see Materials and Methods), but BoNT/D and 481 
BoNT/CD were important as well for differential immunisation, screening, and for validation 482 
studies. To address this issue, single-chain derivatives of BoNT/C and D with drastically 483 
reduced biological activity (scBoNT/Ci, ~500,000-fold less active; scBoNT/Di, ~10,000-fold 484 
less active in an hemidiaphragm assay) as well as isolated HC-fragments of BoNT/C and 485 
BoNT/D (HC/C and HC/D) were recombinantly expressed in E. coli and purified to 486 
homogeneity. BALB/c and NMRI mice were repeatedly immunised with recombinant 487 
scBoNT/Ci, scBoNT/Di, HC/C, HC/D, or mixtures thereof. Serum antibody titres were regularly 488 
tested by indirect ELISA against the purified, natural toxins or single-chain recombinant 489 
proteins. In total, four fusions were performed and more than 12,000 hybridoma supernatants 490 
were screened for the production of specific mAbs (Table 1). Out of 55 positive clones, 11 491 
most promising hybridoma clones providing superior results in indirect ELISA were selected, 492 
purified by affinity-chromatography, and further characterised. In addition to the newly 493 
 
 
generated mAbs, a panel of mAbs available at L. Bellanger’s laboratory (CEA, France), 494 
which were produced by immunisation against recombinant HC/C or HC/D and screening 495 
against natural BoNT/C and BoNT/DC, were included in the study for further experiments. 496 
The isotype of all antibodies was determined as either IgG1 or IgG2b by using an antibody 497 
isotyping kit (Table 2). 498 
In order to narrow down the location of the epitopes recognised by the panel of antibodies, 499 
recombinant LC- and HC-fragments as well as the full-length BoNTs – either natural toxins or 500 
single-chain recombinant proteins – were tested for binding of the mAbs in Western blot and 501 
indirect ELISA experiments. Here, both technologies delivered concurrent results (Figure 2, 502 
Table 2 and data not shown). As exemplarily shown in Figure 2A and D for Western blotting, 503 
it turned out that the LC/C and LC/D were recognised by mAbs C394 and D63, respectively. 504 
Antibody clone D967 was able to interact with HC/D (Figure 2E) and the corresponding part 505 
of BoNT/CD. Antibody clone C9 specifically bound to HC/C (Figure 2B), but was 506 
unexpectedly not able to bind the related HC-fragment of BoNT/DC. Indeed, among 42 clones 507 
initially identified to be specific for HC/C, only two mAbs, clones HCC10S and HCC2378, were 508 
able to bind to the HC-fragment of both BoNT/C (Figure 2C and F) and the corresponding part 509 
of BoNT/DC. A possible explanation could be that BoNT/C and DC show a reduced 510 
sequence identity of approximately 74% in their HC-fragments, this being a considerably 511 
lower homology than the sequence identities observed among the other related LC- and HC-512 
fragments (> 91.6%) for which cross-reacting antibodies could be obtained. This lower 513 
sequence identity between HC/C and HC/DC is paralleled by a divergent binding pattern to 514 
cell surface receptors: While HC/C has been shown to interact with two ganglioside residues, 515 
HC/DC binds one ganglioside plus the protein receptor synaptotagmin.34-36, 40  516 
For all antibodies, binding affinity was analysed by surface plasmon resonance (SPR) 517 
against serial dilutions of scBoNT/C or scBoNT/Di, respectively. Association (ka) and 518 
dissociation (kd) rate constants were calculated from a 1:1-model-based fit.73 All mAbs 519 
showed high binding affinities with equilibrium dissociation constants (KD) between 10–9 to 520 
10–12 M towards their corresponding recombinant scBoNT (Table 2). Interestingly, two mAbs 521 
(C1352 and C2574) were identified that recognised both the HC/C- and the HC/D-fragment in 522 
indirect ELISA (Table 2). For both mAbs, SPR analysis showed a preference for BoNT/C 523 
over BoNT/D, and the results were in line with a higher reactivity towards HC/C than HC/D in 524 
the indirect ELISA experiments (not shown). As specificity control, all antibodies were also 525 
tested against BoNT serotypes A, B, E, F, and G and their corresponding high molecular 526 




Establishing sandwich ELISAs for specific detection and differentiation of BoNT/C, D, 529 
and their mosaic variants 530 
Based on the results of the antibody characterisation, combinations of mAbs were tested for 531 
the specific and differential recognition of BoNT/C, D, CD, and DC. Here, in each case the 532 
mosaic structure of the four toxins was taken into account by including one antibody directed 533 
against the LC of the toxin and the other antibody directed against the HC-domain. The 534 
principle is schematically displayed in Figure 3A where the different mAbs binding to related 535 
sub-fragments of the four BoNTs are indicated in the same colour. We determined the ideal 536 
antibody pair for each individual toxin in buffered solution. An antibody pair was considered 537 
optimal when it specifically detected its corresponding antigen with high sensitivity, without 538 
any cross-reactivity to any of the other four toxins. As antigens, the commercially available 539 
purified BoNT/C and BoNT/DC (the latter sold as BoNT/D51) or recombinantly expressed 540 
scBoNT/C, scBoNT/CD, and scBoNT/D were used.  541 
For specific detection of BoNT/C, it turned out that a combination of mAb C394 which binds 542 
at the LC of BoNT/C with biotinylated mAb C9 which recognises HC/C was optimal (Figure 543 
3B). The combination of the same capture mAb C394 with biotinylated mAb D967, an 544 
antibody recognising the HC/D domain, delivered a specific sandwich ELISA for BoNT/CD 545 
(Figure 3C). BoNT/D was optimally detected by a combination of mAb D63 binding to LC/D 546 
as capture antibody and biotinylated mAb D967 recognising HC/D as detection antibody 547 
(Figure 3D). Finally, for specific detection of BoNT/DC, mAb HCC10S was used for capturing, 548 
which binds to the HC-domain of BoNT/C or BoNT/DC, in combination with biotinylated mAb 549 
D63 binding to LC/D (Figure 3E). The different antibody combinations resulted in four highly 550 
specific sandwich ELISAs, each recognising one of the four related BoNTs – either BoNT/C, 551 
D, CD, or DC – with virtually no cross-reactivity among each other (Figure 3B–E, left panel). 552 
Figure 3 (3 B–E, right panel) displays standard curves of three experiments for each of the 553 
four toxins, including a four-parametric curve fit. For all sandwich ELISAs investigated, the 554 
dynamic range of the assay spanned about two to three orders of magnitude above the limit 555 
of detection (LOD). As indicated in Table 3, excellent LODs were reached by the four 556 
individual ELISAs: For BoNT/C, CD, D, or DC, the LOD was determined to be 11.5 pg/mL, 557 
23.8 pg/mL, 2.1 pg/mL, and 16.1 pg/mL, respectively. Thus, all four ELISAs exceed the 558 
sensitivity of the current gold standard, the mouse bioassay, which was reported to detect 559 
167 or 33 pg/mL for BoNT/C or BoNT/DC, respectively.22  560 
In terms of validation, the lower and upper limits of quantification (LLOQ and ULOQ) were 561 
characterised as concentrations where the curvature in the four-parametric curve fit was 562 
maximal, and for each of the four ELISAs the numbers are given in Table 3. The variability of 563 
the four ELISAs was determined at the half-maximal effective concentration (EC50), the point 564 
 
 
of highest precision in the linear range of the ELISA. The intra- and inter-assay precision for 565 
the determination of the toxins were determined as coefficient of variation (Table 3, CV%-566 
intra assay and CV%-inter assay, see Experimental). For the four ELISAs, the mean intra-567 
assay precision was determined as between 3.3 and 6.4% (Table 3), similar to or better than 568 
within-run precisions reported for other BoNT-specific ELISAs.59, 74-78 The mean inter-assay 569 
precision for the four ELISAs ranged from 8.2 to 24.4% (Table 3), again similar to other 570 
BoNT-specific ELISAs.59, 74, 76-78  571 
The high specificity and sensitivity of the four ELISAs developed in this work represent a 572 
significant technical improvement over other immunoassays described for BoNT/C, CD, D, or 573 
DC that are non-discriminatory on the mosaic variants. Some do not even properly 574 
differentiate between BoNT/C and D – and mostly provide LODs in the range of 250–1500 575 
pg/mL.46-48, 79, 80 An exception was the most recent ELISA described as multiplex approach to 576 
detect six BoNT serotypes including BoNT/C and DC which reached sensitivities similar to 577 
those of the ELISAs established in this work (LODs: 2.2 and 0.9 pg/mL for BoNT/C and DC, 578 
respectively).50 Some of the older assays were relying solely on polyclonal antibodies that 579 
may not necessarily detect the BoNT molecule itself but accessory proteins or unrelated 580 
proteins found in Clostridia supernatants.49, 81  581 
 582 
Different mass spectrometric approaches for differentiation and identification of 583 
BoNT/C, D, and their mosaic variants  584 
To confirm the ELISA-based data on a functional level, our newly developed mAbs specific 585 
for LC- or HC-fragments of BoNTs were evaluated as tools for Endopep-MS assays. In 586 
different approaches, specific immunoaffinity enrichment steps were followed by incubation 587 
with artificial SNAP-25 (for BoNT/C and CD51) or VAMP-2 (for BoNT/D and DC64) substrates 588 
and MS-based detection of cleavage products. To this end, it has to be taken into account 589 
that BoNT/C and CD cleave the SNAP-25 substrate at the very same position, so that they 590 
cannot be differentiated by their endopeptidase activity alone. Similarly, BoNT/D and DC 591 
cleave the VAMP-2 peptide at the very same position.  592 
On this background, two different Endopep-MS approaches were tested: in the first setting, 593 
the BoNTs were captured with a mixture of two mAbs specifically binding to the LC-domain 594 
of either BoNT/C and CD (mAb C394) or BoNT/D and DC (mAb D63), and LC activity was 595 
detected as described51, 64. In this approach, the light chain activity can be monitored by 596 
determining the BoNT/C-type or BoNT/D-type endopeptidase activity, but without 597 
differentiation of the mosaic variants. This is highlighted in Table 4 by the exemplary analysis 598 
of bacterial supernatants from BoNT/C-, CD-, DC-, and D-producing strains. Here, we used a 599 
representative group of four C. botulinum Group III strains, one producing BoNT/C complex 600 
 
 
(strain NCTC8548), one producing BoNT/CD complex (strain C6814), one producing BoNT/D 601 
complex (strain D4947), and one producing BoNT/DC complex (strain Eppendorf). Using the 602 
Endopep-MS approach described, the four strains could be divided into two strains with 603 
either BoNT/C-type cleavage activity or BoNT/D-type cleavage activity, but without 604 
discrimination of the mosaics. The LOD of this type of assay was determined to be 5 pg/mL 605 
for BoNT/D, 50 pg/mL for BoNT/DC, and 1 ng/mL for BoNT/C and BoNT/CD on toxin-spiked 606 
buffer samples (data not shown). This endopeptidase assay format reproduced data 607 
obtained by Moura et al. on BoNT/C and DC using a set of polyclonal capture antibodies.51 608 
With respect to sensitivity, our assay reached similar results using monoclonal antibodies.51 609 
Only very recently the same group was able to improve the limited sensitivity of the BoNT/C-610 
type activity assay by a factor of 200 by introducing a novel artificial peptide substrate.82  611 
In the second setting, the veterinary BoNTs were captured in two parallel reactions using 612 
either a mAb specifically binding to the HC-fragment of BoNT/C and DC (mAb HCC2378, anti-613 
HC/C) or BoNT/D and CD (mAb D967, anti-HC/D), and the endopeptidase activity was 614 
detected after incubation with a mixture of BoNT/C and D substrates by mass spectrometry. 615 
This Endopep-MS format delivered an LOD similar to that of the previously mentioned 616 
Endopep-MS format when purified toxins or recombinant single chain toxins were measured 617 
(data not shown). Based on the mosaic structure of the four BoNTs, theoretically this 618 
approach of capturing the toxins via the HC-domain plus detection of endopeptidase activity 619 
of LC should directly allow for the determination of the different BoNT mosaic variants. 620 
Indeed, as shown in Table 4 and Figure 4B, the approach delivered correct results on the 621 
four representative bacterial supernatants from BoNT/C-, CD-, DC-, and D-producing strains. 622 
A combination of capturing via anti-HC/C plus detection of C-type cleavage activity identifies 623 
strain NCTC8548 as BoNT/C-producing strain; capturing via anti-HC/D plus detection of C-624 
type cleavage activity identifies strain C6814 as BoNT/CD. Similarly, the capturing via anti-625 
HC/D plus detection of D-type cleavage activity identifies strain D4947 as BoNT/D producer; 626 
finally, capturing via anti-HC/C plus detection of D-type cleavage activity identifies strain 627 
Eppendorf as BoNT/DC producer. The results perfectly confirm the ELISA data presented 628 
above (Figure 4A). 629 
This differentiating Endopep-MS approach is only the second assay published that is able to 630 
discriminate the four closely related veterinary BoNTs, including discrimination of the mosaic 631 
variants in vitro on a functional level. A related approach was very recently published by 632 
Björnstad et al. who used one mAb to capture all four toxin types by a common epitope on 633 
the HN-domain, followed by determination of BoNT/C- or BoNT/D-type cleavage activity.22 In 634 
a second reaction, a different mAb was used for enrichment that specifically bound to the 635 
HC-fragment of two of the four toxin types, allowing the discrimination of the mosaic variants. 636 
 
 
In our approach, the capturing step via two mAbs directly targets the different HC-domains 637 
and is combined with the detection of the LC activity, thus delivering straightaway the 638 
serotype including discrimination of mosaic variants.  639 
To finally verify the results obtained by ELISA and Endopep-MS assay, we aimed at 640 
identifying BoNT/C, D, and their mosaic variants by protein sequencing using liquid 641 
chromatography (LC)-MS/MS analysis of the four representative culture supernatants from 642 
BoNT/C-, CD-, D-, and DC-producing strains. To this end, the BoNTs were immunocaptured 643 
by their LC with mAb C394 to enrich for BoNT/C and CD or with mAb D63 to enrich for 644 
BoNT/D and DC. After tryptic digest, they were subjected to LC-MS/MS analysis. As shown 645 
in Table 4 and in Supplementary Information Fig. S1, the four neurotoxins were 646 
unambiguously identified on the protein level with a sequence coverage of 81% for BoNT/C 647 
(strain NCTC8548), 61% for BoNT/CD (strain C6814), 65% for BoNT/D (strain D4947), and 648 
71% for BoNT/DC (strain Eppendorf), respectively. This high sequence coverage has been 649 
obtained on the basis of the concentration of toxins present in the four representative culture 650 
supernatants, as determined by our newly developed sandwich ELISAs (Table 4, 651 
concentration range between 0.4 mg/mL and 11.1 mg/mL). 652 
To our knowledge, not all of the four veterinary BoNTs have been analysed by protein 653 
sequencing using LC-MS/MS analysis before; this is probably due to the lack of purified 654 
BoNT/CD and BoNT/D or the respective toxin-producing strains. Moura et al. obtained amino 655 
acid sequence coverage of 44% for BoNT/C and 18% for BoNT/DC,51 which could be 656 
increased in a later work to 90% and higher when a sequential triple endoprotease in-gel 657 
digestion protocol was introduced.83  658 
 659 
Validation study: Analysis of bacterial supernatants and comparison of results 660 
obtained with different methods 661 
In the course of a botulism outbreak, laboratory diagnostics depends on a proper 662 
combination of technical approaches to detect both the pathogenic organism and the toxin. A 663 
successful strategy combines fast and easy screening methods with confirmation assays 664 
providing information on the activity and/or identity of the toxin. The detection, isolation, and 665 
genetic characterisation of the toxin-producing strain all deliver important additional 666 
information in an epidemiological investigation.42 With respect to BoNT/C, CD, D, and DC, 667 
the main problem addressed in this work was the lack of easy and still highly specific and 668 
sensitive screening tools that allowed for direct discrimination of mosaic variants. It was 669 
important to put the ELISA results obtained in a larger context and to ask for the applicability 670 
and reliability of the ELISAs in the context of alternative genetic (real-time PCR) or activity-671 
 
 
based assays (mouse bioassay [MBA], Endopep-MS assays). To this end, the representative 672 
panel of four C. botulinum Group III strains producing either BoNT/C, CD, D, or DC in their 673 
naturally occurring complexed form was tested with a set of different methods including 674 
different real-time quantitative (q)PCR protocols and MBA. Data obtained before by the four 675 
ELISAs, by Endopep-MS, and LC-MS/MS approaches were corroborated on the genetic 676 
level by qPCR20, 43 and by MBA, and 100 % concordance of results was obtained (Table 4).  677 
While these results were encouraging, they had to be challenged with a larger panel of 678 
C. botulinum supernatants. To this end, blinded bacterial culture supernatants were analysed 679 
from 39 C. botulinum strains isolated in the course of veterinary botulism outbreaks in 680 
Europe. Based on the four ELISAs developed in this work, the 39 strains could clearly be 681 
assigned to 6 BoNT/C-, 27 BoNT/CD-, two BoNT/D-, and four BoNT/DC-producing strains 682 
(Table 5). An identical assignment was obtained by the technically independent qPCR, and 683 
the presence of functionally active toxin was shown by either MBA and/or Endopep-MS 684 
assay. 685 
In a second step, we tested the four ELISAs for cross-reactivity against a number of other 686 
Clostridia strains. These included C. botulinum Group I, II, and IV strains expressing 687 
serotypes A, B, E, F, and G, their non-toxic counterparts, and strains of C. novyi sensu lato 688 
(Table 6). All had been checked by qPCR55 for the presence of BoNT genes, and neurotoxin 689 
production was also confirmed by mouse bioassay, if applicable. All ELISA results were 690 
found to be in perfect agreement with the results obtained by qPCR, with no cross-reactivity 691 
observed against other bacterial supernatants.  692 
While the first validation involved culture supernatants from isolated, pure strains, we went a 693 
step further and tested anaerobic enrichment cultures from veterinary botulism case material 694 
which represent relatively crude materials. Inoculating suspicious sample material into an 695 
anaerobic enrichment culture often allows spore germination and toxin production even if 696 
C. botulinum was present in the inoculum in low spore numbers. Such an enrichment step 697 
has been aiding botulism diagnosis for a long time84, 85 and has been proposed for the 698 
detection of Group III cases either via PCR43, 86 or by immunoassays45. Apart from 699 
C. botulinum, other bacteria might also grow and release their products of metabolism into 700 
the medium. Therefore such culture supernatants are more challenging because the toxin is 701 
often present in lower concentrations. Moreover, the cultures contain additional compounds 702 
which could possibly interfere with the assay. We analysed 23 primary enrichment cultures 703 
from natural veterinary botulism cases occurring in France and Germany, all tested 704 
previously by qPCR.20, 43 All 21 avian botulism cases were found to be positive for BoNT/CD, 705 
while two cases in cattle were positive for BoNT/DC in concordance with the qPCR and 706 
Endopep-MS results, while no false negative results were observed (Table 7).  707 
 
 
Taken together, the validation study showed a 100% concordance of results obtained by the 708 
four newly developed sandwich ELISAs specific for BoNT/C, D, and their mosaic variants 709 




The majority of veterinary botulism cases are caused by C. botulinum Group III strains which 712 
can produce the closely related toxins BoNT/C, BoNT/D, and their mosaic variants BoNT/CD 713 
and BoNT/DC. Based on novel mAbs, in the current work we have established a set of 714 
technically independent approaches that allow for the correct and precise determination and 715 
quantification of the toxin type, including differentiation of mosaic variants at different levels. 716 
Basically, the different methods are intended to be placed in an optimised workflow as step-717 
by-step approach and can be applied in routine and/or expert laboratories. (i) In a first 718 
screening step, the four highly specific ELISAs deliver information on which specific 719 
veterinary toxin is present in a suspicious sample and allow for its quantification down to a 720 
few pg/mL. This is a clear advantage over genetic methods identifying potentially toxin-721 
containing samples, which, however, do not detect the toxin itself. The four ELISAs can be 722 
readily performed in routine clinical or microbiological laboratories and do not need 723 
sophisticated technical equipment. The current work has shown that the ELISAs developed 724 
are highly specific, highly sensitive, and robust tools that give correct results on real 725 
veterinary sample materials. (ii) In a second step, the results obtained by ELISA screening 726 
can be corroborated on the functional level, showing that active toxin is present in a 727 
suspicious sample. Here, one Endopep-MS format presented gives evidence for either C-728 
type or D-type activity in the sample, and this method can be used as replacement method 729 
for the classical MBA in botulism diagnostics. This format is easier to perform technically and 730 
requires less hands-on time (one enrichment and cleavage reaction per sample with both 731 
artificial substrates to demonstrate either C-type or D-type activity) than the second 732 
Endopep-MS format presented that allows for the discrimination of all four veterinary BoNTs. 733 
In this second format, the veterinary toxins are captured in two parallel enrichment reactions 734 
either with an anti-HC/C or an anti-HC/D mAb, followed by a cleavage reaction with both 735 
artificial substrates (corresponding to two parallel tests per sample). As to the applicability of 736 
the two Endopep-MS approaches, the first approach might be more appropriate if the overall 737 
toxicity of a sample should be demonstrated, while the second approach delivers more 738 
detailed information e.g. in the course of an epidemiological investigation. Due to the 739 
technical equipment and expertise necessary, both methods might be restricted to expert 740 
laboratories. In future, both formats could be further developed into quantitative Endopep-MS 741 
methods by implementation of stable isotope-labelled peptides for quantification.51, 87 (iii) 742 
Finally, if unambiguous identification of toxin is necessary, e.g. in the case of a forensic 743 
investigation, a proteomic approach can be applied: an appropriate combination of mAbs for 744 
enrichment plus tryptic digest and LC-MS/MS analysis resulted in a high sequence coverage 745 
of all four veterinary toxins (61–81%) from bacterial culture supernatants. This method could 746 
be very helpful in case little, degraded, or no DNA is present in a suspicious sample material 747 
 
 
and genomic sequencing is prevented. Alternatively, if  DNA is available, this step can be 748 
substituted or complemented by a sequencing approach. Again, these approaches are 749 
presumably applicable in highly specialised laboratories. While the different methods (i) to 750 
(iii) vary with respect to sensitivity, specificity, and unambiguousness, they are appropriate 751 
for complementing each other on a technically independent level to deliver preliminary, 752 
confirmed, and – all of them combined – unambiguous results. Our comprehensive validation 753 
study including 39 culture supernatants from toxin-producing C. botulinum Group III strains, 754 
13 toxin-producing C. botulinum Group I, II, or IV strains, 21 non-neurotoxin-producing 755 
Clostridia, and 23 primary enrichment cultures resulted in conclusive results on all technical 756 
levels. Specifically, the four differentiating ELISAs already yielded correct results on BoNT/C, 757 
D, and their mosaic variants on all sample materials tested, with no false-positive or false-758 
negative results. Therefore, the differentiating ELISAs represent highly reliable, sensitive, 759 
and easy screening tools for the fast analysis of veterinary botulism cases, which should aid 760 
future field investigations of botulism outbreaks, the acquisition of epidemiological data, and 761 
support routine veterinary quality control measures, e.g. feed lot analysis. 762 
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Figure Legends 942 
Figure 1: 943 
Schematic domain organisation of BoNT/C, BoNT/D, and their related mosaic variants. All 944 
BoNT serotypes are composed of a light chain (LC) and a heavy chain (HC), connected via a 945 
disulphide bond. The HC can be further subdivided into N-terminal translocation domain (HN) 946 
and C-terminal receptor binding domain (HC). BoNT/C, BoNT/D, and their mosaic variants 947 
BoNT/CD and BoNT/DC show a high degree of identity on the protein level. Genbank entries 948 
of 18 different amino acid sequences were aligned and compared using Geneious 7.1.4. as 949 
described within the Experimental section. For each of the four toxins, two to seven 950 
sequences available in the database were compared with each other, and percent identity is 951 
indicated. Highly homologous domains are indicated in similar colours.  952 
 953 
Figure 2: 954 
Immunoblots demonstrating mAb specificity. Recombinantly expressed light chains (LC) and 955 
HC fragments of BoNT/C and D were separated on 10% SDS-PAGE and transferred onto 956 
PVDF membranes. The membranes were incubated with the following antibodies: C394 (A), 957 
C9 (B), HCC2378 (C), D63 (D), D967 (E), and HCC10S (F), followed by detection with 958 
biotinylated anti-mouse antibody and a streptavidin-alkaline phosphatase-conjugate and 959 
CDP-Star as substrate. 960 
 961 
Figure 3: 962 
Highly specific sandwich ELISAs detecting and differentiating BoNT/C, CD, D, or DC. The 963 
principle of the four differentiating ELISAs for the veterinary BoNTs is schematically 964 
displayed in (A). The following combination of antibodies was used in an amplified sandwich 965 
ELISA setting: (B) BoNT/C ELISA: mAb C394 plus biotinylated mAb C9; (C) BoNT/CD 966 
ELISA: mAb C394 plus biotinylated mAb D967; (D) BoNT/D ELISA: mAb D63 plus 967 
biotinylated mAb D967; and (E) BoNT/DC ELISA: mAb HCC10S plus biotinylated mAb D63. 968 
For each of the four ELISAs, the first-mentioned mAb was immobilised onto microtitre plates. 969 
After blocking of non-specific binding, 200 ng/mL of each toxin or BSA (left panel) or serial 970 
dilutions of the corresponding toxin (from 1 µg/mL to 1 pg/mL, right panel) were added. 971 
Detection was performed using a biotinylated detection antibody as indicated above, followed 972 
by streptavidin-peroxidase conjugate and TMB. For the right panel, three representative 973 
 
 
measurements performed in triplicate are overlaid. The left panel summarises three 974 
independent experiments.  975 
 976 
Figure 4: 977 
Detection and differentiation of four representative BoNT/C-, CD-, D-, and DC-producing 978 
bacterial culture supernatants by sandwich ELISA and Endopep-MS reaction. 979 
(A) Differentiating sandwich ELISA. Bacterial supernatants containing BoNT/C (NCTC8548), 980 
BoNT/CD (C6814), BoNT/D (D4947), and BoNT/DC (Eppendorf) were tested in 1:10 dilutions 981 
by the four differentiating sandwich ELISA described in Fig. 3. (B) MALDI mass spectra of 982 
BoNT/C, D, and their related mosaic variants by differentiating Endopep-MS. The four 983 
representative bacterial supernatants described above were enriched by mAb HCC2378 984 
directed against the HC of BoNT/C and BoNT/DC (α-HC/C) and in a second independent 985 
reaction by mAb D967 directed against HC of BoNT/D and BoNT/CD (α-HC/D). 986 
Immunocaptured toxins were incubated with synthetic SNAP-25 (C-Sub+, m/z 2911) and 987 
VAMP2-based (D-Sub+, m/z 4496) peptide substrates to detect the LC proteolytic activity of 988 
BoNT/C, CD, or BoNT/D, DC, respectively. Samples containing active BoNT/C and CD lead 989 
to specific C-terminal (C-CT) and N-terminal (C-NT) cleavage peptide products at m/z 1059 990 
and m/z 1871, whereas BoNT/D and DC cleavage products are detected at m/z 1217 (D-CT) 991 
and m/z 3297 (D-NT). 992 
 993 
Graphical entry figure: 994 
Novel monoclonal antibodies enable highly specific immunoassays for the detection, 995 
differentiation, and quantification of related botulinum neurotoxin serotypes C, CD, D, and 996 
DC followed by mass-spectrometry-based functional characterisation and identification.  997 
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* The indicated hybridoma were characterised in detail in Table 2; hybridoma clones indicated in bold 999 
were used for setting up different ELISAs to detect BoNT/C, D, and their mosaic variants in Figure 3 or 1000 
for Endopep-MS analysis. 1001 
 1002 
  1003 
 
 
Table 2. Characterisation of mAb generated against fragments of BoNT/C and D. 1004 
Antibody Species Isotype Affinity KD [M] Source Specificity* 
     BoNT/C BoNT/D 
     LC HC LC HC 
C394 mouse IgG2b, λ    < 10–12   (a) RKI +    
C9 mouse IgG2b, κ 4 × 10–10   (a) RKI  +   
HCC10S mouse IgG1, κ 1 × 10–10   (a) CEA  +   
HCC2378 mouse IgG1,κ 2 × 10–10   (a) RKI  +   
D63 mouse IgG2b, κ 4 × 10–10   (b) RKI   +  
D967 mouse IgG1, λ 1 × 10–10   (b) RKI    + 
C1916 mouse IgG1, κ 6 × 10–12   (a) RKI +    
C1352 mouse IgG2b, κ 5 × 10–10   (a)/ 1 × 10–7   (b) RKI  +  + 
C2574 mouse IgG1, κ 2 × 10–9     (a)/ 7 × 10–8   (b) RKI  +  + 
HCC141 mouse IgG1, κ 4 × 10–11   (a) RKI  +   
HCC515 mouse IgG2b, κ 5 × 10–10   (a) RKI  +   
HCC1304 mouse IgG1, κ 1 × 10–9     (a) RKI  +   
* Specificity is shown as derived from indirect ELISA and Western blot experiments on recombinant 1005 
fragments of BoNT/C or BoNT/D (see Figure 2). Affinity was measured by surface plasmon resonance 1006 
on (a) scBoNT/C or (b) scBoNT/Di, respectively. Hybridoma clones indicated in bold were used for 1007 
setting up different ELISAs to detect BoNT/C, D, and their mosaic variants in Figure 3 or for Endopep-1008 







Table 3. Validation of sandwich ELISA specific for BoNT/C, CD, D, or DC.  1014 














BoNT/C 11.5 0.4 4.4 1.3 5.8 24.4 
C394 vs. 
D967-bio 
scBoNT/CD 23.8 0.2 2.4 0.7 3.3 17.1 
D63 vs. 
D967-bio 
scBoNT/D   2.1 0.2 2.5 0.7 3.6   8.2 
HCC10 vs. 
D63-bio 
BoNT/DC 16.1 0.3 4.3 1.1 6.4 24.0 
* For each specific ELISA, the LOD determined on purified or recombinant toxins, the lower and upper 1015 
limit of quantification, the EC50, as well as coefficients of variation are shown. Indicated in the first 1016 
place is the mAb used as capture antibody, and in the second place the mAb used as biotinylated 1017 
(bio) detection antibody. LOD: Limit of detection; LLOQ: Lower limit of quantification; ULOQ: Upper 1018 
limit of quantification; EC50: half maximal effective concentration; CV: coefficient of variation 1019 




Table 4. Exemplary analysis of bacterial culture supernatants analysed in detail by 1022 
sandwich ELISA, real-time quantitative PCR, MBA, different Endopep-MS formats, and 1023 
LC-MS/MS analysis. 1024 
 1025 










C NCTC8548 C C + C-type C BoNT/C  
(81%) 
CD C6814 CD CD + C-type CD BoNT/CD 
(61%) 
D D4947 D D + D-type D BoNT/D  
(65%) 
DC Eppendorf DC DC + D-type DC BoNT/DC 
(71%) 
 1026 
a  Serotype identified by application of the four ELISAs developed in this work. Quantification of the 1027 
representative supernatants yielded: 1.8 mg/mL (NCTC8548), 0.4 mg/mL (CD6814), 6.7 mg/mL 1028 
(D4947), and 11.1 mg/mL (Eppendorf) (mean of three independent measurements). 1029 
b  Real-time PCR according to Woudstra et al.43 1030 
c  Supernatant tested positive by mouse bioassay (MBA), no serotyping performed. 1031 
d  Endopep-MS assay based on immunoaffinity enrichment using LC-specific mAb C394 specific for 1032 
the LC of BoNT/C and CD and mAb D63 specific for BoNT/D and DC, respectively. This type of 1033 
assay delivers information on the C-type cleavage activity (without discrimination of C and CD) or D-1034 
type cleavage activity (without discrimination of D and DC). 1035 
e  Endopep-MS assay based on immunoaffinity enrichment using HC-specific mAbs HCC2378 or D967, 1036 
respectively. This type of assay allows discrimination of BoNT/C, D, and their respective mosaic 1037 
variants on a functional level. 1038 
f  Protein sequence coverage obtained by enrichment with mAbs C394 or D63 followed by tryptic 1039 
digest and LC-MS/MS analysis using an Orbitrap instrument (for more information on sequence 1040 
coverage, see Supplementary Information Fig. S1). 1041 





Table 5. Bacterial culture supernatants from a panel of C. botulinum strains tested by 1045 
sandwich ELISA, real-time quantitative PCR, MBA, and Endopep-MS. 1046 
Lab. no. Source ELISA
a qPCRb MBAc Endopep-MS
d 
(LC activity) 
14-044 strain C C + C-type 
14-045 strain C C + C-type  
14-046 strain C C + C-type 
14-047 strain C C + C-type 
NCTC8548 strain C C +  C-type 
12-149-01 strain C C n.a. C-type 
14-048 poultry CD CD + C-type 
14-049 duck, swab CD CD + C-type 
14-050 turkey, swab CD CD + C-type 
14-051 turkey, spleen CD CD + C-type 
14-052 poultry CD CD + C-type 
14-053 unknown CD CD + C-type 
14-054 chicken CD CD + C-type 
14-055 chicken CD CD + C-type 
14-056 duck, faeces CD CD + C-type 
14-057 chicken CD CD + C-type 
14-058 unknown CD CD n.a. C-type 
14-059 poultry CD CD n.a. C-type 
14-060 poultry CD CD n.a. C-type 
14-061 poultry CD CD n.a. C-type 
14-062 poultry CD CD + C-type 
14-063 poultry CD CD + C-type 
14-064 poultry CD CD + C-type 
14-065 turkey, faeces CD CD + C-type 
14-066 duck, faeces CD CD + C-type 
14-067 poultry CD CD + C-type 
14-068 poultry CD CD + C-type 
14-069 duck, faeces CD CD + C-type 
14-070 poultry CD CD + C-type 
C6814 strain CD CD + C-type 
14-006-01 cattle CD CD n.a. C-type 
14-007-01 cattle CD CD n.a. C-type 
14-008-01 cattle CD CD n.a. C-type 
14-071 unknown D D + D-type 
D4947 strain D D + D-type 
14-072 bovine, faeces DC DC + D-type 
14-073 bovine, faeces DC DC + D-type 
14-074 bovine, faeces DC DC + D-type 
Eppendorf strain DC DC + D-type 
a Serotype identified by application of the four ELISAs developed in this work. b Real-time PCR according to Woudstra et al.43. 1047 
c Mouse bioassay (MBA, no serotyping performed). n.a.: not analysed. d Endopep-MS assay to determine LC activity (see Table 1048 
4 for details).  1049 
 
 
Table 6. Specificity of ELISA against supernatants of related Clostridia species tested 1050 
by sandwich ELISA, real-time quantitative PCR, and MBA.  1051 
  Results of serotyping obtained by 
different methods 
Strain name Species ELISAa     qPCRb MBAc 
NCTC 7272 C. botulinum (Group I) – A + 
NCTC 2012 C. botulinum (Group I) – A + 
Chemnitz C. botulinum (Group I) – A + 
Friedrichshain C. botulinum (Group I) – A + 
NCTC7273 C. botulinum (Group I) – B + 
2293 C. botulinum (Group I) – B + 
KL34/08 C. botulinum (Group I) – B + 
Wittenmoor C. botulinum (Group II) – E + 
Beluga C. botulinum (Group II) – E n.a. 
REB1718B C. botulinum (Group II) – E + 
H092.2.01 C. botulinum (Group II) – E + 
NCTC10281 C. botulinum (Group I) – F + 
CECT4615 C. botulinum (Group IV) – G n.a. 
13-119-01 C. baratii – – n.a. 
H173852A-01 C. berijerinckii – – n.a. 
11-053-20 C. botulinum, Group II atoxic – – n.a. 
13-028-01 C. butyricum – – n.a. 
13-040-01 C. butyricum – – n.a. 
13-118-01 C. bifermentans – – n.a. 
14-005-05 C. difficile – – n.a. 
12-108-01 C. glycolicum – – n.a. 
13-159-02 C. hiranonis – – n.a. 
12-109-01 C. innocuum – – n.a. 
12-019-01 C. novyi – – n.a. 
12-135-05 C. paraputrificum – – n.a. 
14-003-01 C. perfringens – – n.a. 
13-123-04 C. sartagoforme – – n.a. 
12-007 C. scindens – – n.a. 
09-038 C. septicum – – n.a. 
13-039-01 C. sordellii – – n.a. 
DSM1734 C. sporogenes – – n.a. 
13-151-02 C. tertium – – n.a. 
14-081-01 C. subterminale – – n.a. 
3642 C. tetani – – n.a. 
a tested by application of the four ELISAs developed in this work.  1052 
b RT-PCR according to Kirchner et al.55 (serotypes BoNT/A, B, E, and F). 1053 
c Mouse bioassay (MBA).  1054 
n.a.: not analysed. 1055 
 
 
Table 7. Primary enrichment cultures of veterinary botulism cases tested by sandwich 1056 
ELISA, real-time quantitative PCR, and Endopep-MS. 1057 
 1058 
a Serotype identified by application of the four ELISAs developed in this work.  1059 
b Real-time PCR according to Woudstra et al.43.  1060 
c Endopep-MS assay to determine LC activity (see Table 4 for details). 1061 
  1062 
  
Results of serotyping obtained by different 
methods 
Lab. no. Source of 
enrichment culture 
ELISAa    qPCRb Endopep-MS 
(LC activity)c 
14-220 duck, swab CD CD C-type 
14-221 turkey, spleen CD CD C-type  
14-222 chicken, intestine CD CD C-type 
14-223 turkey, liver CD CD C-type 
14-225 chicken, faeces CD CD C-type 
14-226 chicken CD CD C-type 
14-228 chicken CD CD C-type 
14-229 duck, faeces CD CD C-type 
14-230 chicken CD CD C-type 
14-231 chicken, faeces CD CD C-type 
14-232 chicken, faeces CD CD C-type 
14-233 chicken CD CD C-type 
14-234 chicken CD CD C-type 
14-235 chicken CD CD C-type 
14-236 guinea fowl, faeces CD CD C-type 
14-237 duck, faeces CD CD C-type 
14-238 turkey CD CD C-type 
14-240 chicken CD CD C-type 
14-241 chicken CD CD C-type 
14-242 chicken CD CD C-type 
14-243 duck, faeces CD CD C-type 
14-224 bovine, faeces DC DC D-type 
14-239 bovine, faeces DC DC D-type 
 
 
Figure 1 1063 
 1064 
 1065 
  1066 
 
 
Figure 2 1067 
 1068 
 1069 
  1070 
 
 





Figure 4 1074 
 1075 
 1076 
Detection, differentiation, and identification  
of botulinum neurotoxin serotypes C, CD, D, and DC by highly 
specific immunoassays and mass spectrometry 
 
Eva-Maria Hansbauer1*, Martin Skiba1*, Tanja Endermann1*, Jasmin Weisemann2, Daniel 
Stern1, Martin B. Dorner1, Friedrich Finkenwirth1, Jessica Wolf1, Werner Luginbühl3, Ute 
Messelhäußer4, Laurent Bellanger5, Cédric Woudstra6, Andreas Rummel2, Patrick Fach6, 
Brigitte G. Dorner1, # 
 
1  Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch 
Institute (RKI), Berlin, Germany 
2  Institut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany 
3 ChemStat, Bern, Switzerland 
4  Bavarian Health and Food Safety Authority, Oberschleißheim, Germany 
5  Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratory 
Innovative Technologies for Detection and Diagnostics, Bagnols-sur-Cèze, France 
6  French Agency for Food, Environmental and Occupational Health Safety (ANSES), Food 
Safety Laboratory, Maisons-Alfort, France 
* these authors contributed equally to this work 
 
# Corresponding Author: 
Brigitte G Dorner, Biological Toxins, Centre for Biological Threats and Special Pathogens, 
Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany 
Tel: +49-30 18 754 2500 







Supplementary Fig: S1 
 




   1  MPITINNFNY SDPVDNKNIL YLDTHLNTLA NEPEKAFRIT GNIWVIPDRF 
  51  SRNSNPNLNK PPRVTSPKSG YYDPNYLSTD SDKDTFLKEI IKLFKRINSR 
 101  EIGEELIYRL STDIPFPGNN NTPINTFDFD VDFNSVDVKT RQGNNWVKTG 
 151  SINPSVIITG PRENIIDPET STFKLTNNTF AAQEGFGALS IISISPRFML 
 201  TYSNATNDVG EGRFSKSEFC MDPILILMHE LNHAMHNLYG IAIPNDQTIS 
 251  SVTSNIFYSQ YNVKLEYAEI YAFGGPTIDL IPKSARKYFE EKALDYYRSI 
 301  AKRLNSITTA NPSSFNKYIG EYKQKLIRKY RFVVESSGEV TVNRNKFVEL 
 351  YNELTQIFTE FNYAKIYNVQ NRKIYLSNVY TPVTANILDD NVYDIQNGFN 
 401  IPKSNLNVLF MGQNLSRNPA LRKVNPENML YLFTKFCHKA IDGRSLYNKT 
 451  LDCRELLVKN TDLPFIGDIS DVKTDIFLRK DINEETEVIY YPDNVSVDQV 
 501  ILSKNTSEHG QLDLLYPSID SESEILPGEN QVFYDNRTQN VDYLNSYYYL 
 551  ESQKLSDNVE DFTFTRSIEE ALDNSAKVYT YFPTLANKVN AGVQGGLFLM 
 601  WANDVVEDFT TNILRKDTLD KISDVSAIIP YIGPALNISN SVRRGNFTEA 
 651  FAVTGVTILL EAFPEFTIPA LGAFVIYSKV QERNEIIKTI DNCLEQRIKR 
 701  WKDSYEWMMG TWLSRIITQF NNISYQMYDS LNYQAGAIKA KIDLEYKKYS 
 751  GSDKENIKSQ VENLKNSLDV KISEAMNNIN KFIRECSVTY LFKNMLPKVI 
 801  DELNEFDRNT KAKLINLIDS HNIILVGEVD KLKAKVNNSF QNTIPFNIFS 
 851  YTNNSLLKDI INEYFNNIND SKILSLQNRK NTLVDTSGYN AEVSEEGDVQ 
 901  LNPIFPFDFK LGSSGEDRGK VIVTQNENIV YNSMYESFSI SFWIRINKWV 
 951  SNLPGYTIID SVKNNSGWSI GIISNFLVFT LKQNEDSEQS INFSYDISNN 
1001  APGYNKWFFV TVTNNMMGNM KIYINGKLID TIKVKELTGI NFSKTITFEI 
1051  NKIPDTGLIT SDSDNINMWI RDFYIFAKEL DGKDINILFN SLQYTNVVKD 
1101  YWGNDLRYNK EYYMVNIDYL NRYMYANSRQ IVFNTRRNNN DFNEGYKIII 
1151  KRIRGNTNDT RVRGGDILYF DMTINNKAYN LFMKNETMYA DNHSTEDIYA 
1201  IGLREQTKDI NDNIIFQIQP MNNTYYYASQ IFKSNFNGEN ISGICSIGTY 

























   1   MPITINNFNY SDPVDNKNIL YLDTHLNTLA NEPEKAFRII GNIWVIPDRF 
  51  SRDSNPNLNK PPRVTSPKSG YYDPNYLSTD SEKDTFLKEI IKLFKRINSR 
 101  EIGEELIYRL ATDIPFPGNN NTPINTFDFD VDFNSVDVKT RQGNNWVKTG 
 151  SINPSVIITG PRENIIDPET STFKLTNNTF AAQEGFGALS IISISPRFML 
 201  TYSNATNNVG EGRFSKSEFC MDPILILMHE LNHAMHNLYG IAIPNDQRIS 
 251  SVTSNIFYSQ YNVKLEYAEI YAFGGPTIDL IPKSARKYFE EKALDYYRSI 
 301  AKRLNSITTA NPSSFNKYIG EYKQKLIRKY RFVVESSGEV AVDRNKFAEL 
 351  YKELTQIFTE FNYAKIYNVQ NRKIYLSNVY TPVTANILDD NVYDIQNGFN 
 401  IPKSNLNVLF MGQNLSRNPA LRKVNPENML YLFTKFCHKA IDGRSLYNKT 
 451  LDCRELLVKN TDLPFIGDIS DIKTDIFLSK DINEETEVID YPDNVSVDQV 
 501  ILSKNTSEHG QLDLLYPIIE GESQVLPGEN QVFYDNRTQN VDYLNSYYYL 
 551  ESQKLSDNVE DFTFTTSIEE ALDNSGKVYT YFPKLADKVN TGVQGGLFLM 
 601  WANDVVEDFT TNILRKDTLD KISDVSAIIP YIGPALNISN SVRRGNFTEA 
 651  FAVTGVTILL EAFQEFTIPA LGAFVIYSKV QERNEIIKTI DNCLEQRIKR 
 701  WKDSYEWMIG TWLSRITTQF NNISYQMYDS LNYQADAIKD KIDLEYKKYS 
 751  GSDKENIKSQ VENLKNSLDI KISEAMNNIN KFIRECSVTY LFKNMLPKVI 
 801  DELNKFDLKT KTELINLIDS HNIILVGEVD RLKAKINESF ENTIPFNIFS 
 851  YTNNSLLKDI INEYFNSIND SKILSLQNKK NALVDTSGYN AEVRLEGDVQ 
 901  VNTIYTNDFK LSSSGDKIIV NLNNNILYSA IYENSSVSFW IKISKDLTNS 
 951  HNEYTIINSI KQNSGWKLCI RNGNIEWILQ DINRKYKSLI FDYSESLSHT 
1001  GYTNKWFFVT ITNNIMGYMK LYINGELKQS ERIEDLDEVK LDKTIVFGID 
1051  ENIDENQMLW IRDFNIFSKE LSNEDINIVY EGQILRNVIK DYWGNPLKFD 
1101  TEYYMINYNY IDRYIAPKNN ILVLVQYSDI SKLYTKNPIT IKSAANKNPY 
1151  SRILNGDDIM FHMLYDSREY MIIRDTDTIY ATQGGQCSKN CVYALKLQSN 
1201  LGNYGIGIFS IKNIVSQNKY CSQIFSSFMK NTMLLADIYK PWRFSFENAY 

























   1   MTWPVKDFNY SDPVNDNDIL YLRIPQNKLI TTPVKAFMIT QNIWVIPERF 
  51  SSDTNPSLSK PPRPTSKYQS YYDPSYLSTD EQKDTFLKGI IKLFKRINER 
 101  DIGKKLINYL VVGSPFMGDS STPEDTFDFT RHTTNIAVEK FENGSWKVTN 
 151  IITPSVLIFG PLPNILDYTA SLTLQGQQSN PSFEGFGTLS ILKVAPEFLL 
 201  TFSDVTSNQS SAVLGKSIFC MDPVIALMHE LTHSLHQLYG INIPSDKRIR 
 251  PQVSEGFFSQ DGPNVQFEEL YTFGGLDVEI IPQIERSQLR EKALGHYKDI 
 301  AKRLNNINKT IPSSWISNID KYKKIFSEKY NFDKDNTGNF VVNIDKFNSL 
 351  YSDLTNVMSE VVYSSQYNVK NRTHYFSRHY LPVFANILDD NIYTIRDGFN 
 401  LTNKGFNIEN SGQNIERNPA LQKLSSESVV DLFTKVCLRL TKNSRDDSTC 
 451  IKVKNNRLPY VADKDSISQE IFENKIITDE TNVQNYSDKF SLDESILDGQ 
 501  VPINPEIVDP LLPNVNMEPL NLPGEEIVFY DDITKYVDYL NSYYYLESQK 
 551  LSNNVENITL TTSVEEALGY SNKIYTFLPS LAEKVNKGVQ AGLFLNWANE 
 601  VVEDFTTNIM KKDTLDKISD VSVIIPYIGP ALNIGNSALR GNFNQAFATA 
 651  GVAFLLEGFP EFTIPALGVF TFYSSIQERE KIIKTIENCL EQRVKRWKDS 
 701  YQWMVSNWLS RITTQFNHIN YQMYDSLSYQ ADAIKAKIDL EYKKYSGSDK 
 751  ENIKSQVENL KNSLDVKISE AMNNINKFIR ECSVTYLFKN MLPKVIDELN 
 801  KFDLRTKTEL INLIDSHNII LVGEVDRLKA KVNESFENTM PFNIFSYTNN 
 851  SLLKDIINEY FNSINDSKIL SLQNKKNALV DTSGYNAEVR VGDNVQLNTI 
 901  YTNDFKLSSS GDKIIVNLNN NILYSAIYEN SSVSFWIKIS KDLTNSHNEY 
 951  TIINSIEQNS GWKLCIRNGN IEWILQDVNR KYKSLIFDYS ESLSHTGYTN 
1001  KWFFVTITNN IMGYMKLYIN GELKQSQKIE DLDEVKLDKT IVFGIDENID 
1051  ENQMLWIRDF NIFSKELSNE DINIVYEGQI LRNVIKDYWG NPLKFDTEYY 
1101  IINDNYIDRY IAPESNVLVL VQYPDRSKLY TGNPITIKSV SDKNPYSRIL 
1151  NGDNIILHML YNSRKYMIIR DTDTIYATQG GECSQNCVYA LKLQSNLGNY 
1201  GIGIFSIKNI VSKNKYCSQI FSSFRENTML LADIYKPWRF SFKNAYTPVA 









   1  MTWPVKDFNY SDPVNDNDIL YLRIPQNKLI TTPVKAFMIT QNIWVIPERF 
  51  SSDTNPSLSK PPRPTSKYQS YYDPSYLSTD EQKDTFLKGI IKLFKRINER 
 101  DIGKKLINYL VVGSPFMGDS STPEDTFDFT RHTTNIAVEK FENGSWKVTN 
 151  IITPSVLIFG PLPNILDYTA SLTLQGQQSN PSFEGFGTLS ILKVAPEFLL 
 201  TFSDVTSNQS SAVLGKSIFC MDPVIALMHE LTHSLHQLYG INIPSDKRIR 
 251  PQVSEGFFSQ DGPNVQFEEL YTFGGSDVEI IPQIERLQLR EKALGHYKDI 
 301  AKRLNNINKT IPSSWSSNID KYKKIFSEKY NFDKDNTGNF VVNIDKFNSL 
 351  YSDLTNVMSE VVYSSQYNVK NRTHYFSKHY LPVFANILDD NIYTIINGFN 
 401  LTTKGFNIEN SGQNIERNPA LQKLSSESVV DLFTKVCLRL TRNSRDDSTC 
 451  IQVKNNTLPY VADKDSISQE IFESQIITDE TNVENYSDNF SLDESILDAK 
 501  VPTNPEAVDP LLPNVNMEPL NVPGEEEVFY DDITKDVDYL NSYYYLEAQK 
 551  LSNNVENITL TTSVEEALGY SNKIYTFLPS LAEKVNKGVQ AGLFLNWANE 
 601  VVEDFTTNIM KKDTLDKISD VSAIIPYIGP ALNIGNSALR GNFKQAFATA 
 651  GVAFLLEGFP EFTIPALGVF TFYSSIQERE KIIKTIENCL EQRVKRWKDS 
 701  YQWMVSNWLS RITTQFNHIS YQMYDSLSYQ ADAIKAKIDL EYKKYSGSDK 
 751  ENIKSQVENL KNSLDVKISE AMNNINKFIR ECSVTYLFKN MLPKVIDELN 
 801  KFDLKTKTEL INLIDSHNII LVGEVDRLKA KVNESFENTI PFNIFSYTNN 
 851  SLLKDMINEY FNSINDSKIL SLQNKKNTLM DTSGYNAEVR VEGNVQLNPI 
 901  FPFDFKLGSS GDDRGKVIVT QNENIVYNAM YESFSISFWI RINKWVSNLP 
 951  GYTIIDSVKN NSGWSIGIIS NFLVFTLKQN ENSEQDINFS YDISKNAAGY 
1001  NKWFFVTITT NMMGNMMIYI NGKLIDTIKV KELTGINFSK TITFQMNKIP 
1051  NTGLITSDSD NINMWIRDFY IFAKELDDKD INILFNSLQY TNVVKDYWGN 
1101  DLRYDKEYYM INVNYMNRYM SKKGNGIVFN TRKNNNDFNE GYKIIIKRII 
1151  GNTNDTRVRG ENVLYFNTTI DNKQYSLGMY KPSRNLGTDL VPLGALDQPM 
1201  DEIRKYGSFI IQPCNTFDYY ASQLFLSSNA TTNRIGILSI GSYSFKLGDD 




Amino acid sequence coverage of immunoextracted BoNT/C, CD, D, and DC after tryptic 
digest and liquid chromatography-tandem mass spectrometry analysis. Culture supernatants 
of Clostridium botulinum strains producing BoNT/C (NCTC8548) and BoNT/CD (C6814) 
were enriched by mAb C394 and BoNT/D (D4947) and BoNT/DC (Eppendorf) were enriched 
by mAb D63 (both mAb are directed against the light chain of the toxins, see Figure 2). 
Immunocaptured toxins were digested by trypsin and resulting peptides were analysed by 
LC-MS/MS. MS/MS evidence was obtained for amino acids marked in red comprising 81% 
sequence coverage for BoNT/C (Q93HT3_CLOBO) (A), 61% for BoNT/CD 
(Q5DW55_CLOBO) (B), 65% for BoNT/D (BXD_CLOBO) (C), and 71% for BoNT/DC 
(C6KZT4_CLOBO) (D).  
 
